Should I Invest In These 5 FTSE 100 Shares?

Can AstraZeneca plc (LON: AZN), Johnson Matthey PLC (LON: JMAT), Smith & Nephew plc (LON: SN), Pearson plc (LON: PSON) and BAE Systems plc (LON: BA) deliver market-beating total returns?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

To me, capital growth and dividend income are equally important. Together, they provide the total return from any share investment and, as you might expect, my aim is to invest in companies that can beat the total return delivered by the wider market.

To put that aim into perspective, the FTSE 100 has provided investors with a total return of around 3% per annum since January 2008.

Quality and value

If my investments are to outperform, I need to back companies that score well on several quality indicators and buy at prices that offer decent value.

So this series aims to identify appealing FTSE 100 investment opportunities and during recent weeks I’ve looked at AstraZeneca (LSE: AZN), Johnson Matthey (LSE: JMAT), Smith & Nephew (LSE: SN), Pearson (LSE: PSON) and BAE Systems (LSE: BA). This is how they scored on my total-return-potential indicators (each score in the table is out of a maximum of 5):

Share AstraZeneca Johnson
Matthey
Smith &
Nephew
Pearson BAE 
Dividend cover 4 4 4 3 3
Borrowings 4 3 4 3 5
Growth 1 2 4 2 2
Price to earnings 2 2 2 4 2
Outlook 2 3 3 3 3
Total (out of 25) 13 14 17 15 15

Pharmaceuticals

A 9% rise in emerging-markets revenue, which accounts for around 21% of sales, wasn’t enough to offset AstraZeneca’s overall 12% revenue decline and 21% fall in core operating profit during the first quarter. The pain is largely due to increased competition since several patents timed-out on some of the firm’s best-selling drugs. Targeted in-house research & development, and an active acquisition programme, are both strategies aimed at restoring a product-development pipeline that can generate further growth. There’s a tempting forward dividend yield of around 5.7% available for those willing to wait for recovery, but I’m happy to watch for the time being.

Platinum-focused products

A poor performance in Johnson Matthey’s Precious Metal Products Division led to declining figures in 2012 after several periods of steady revenue and earnings growth. However, the directors expect tighter vehicle emissions legislation and demand for process technologies’ products, especially in China, to boost sales of the firm’s catalysts, components and chemical processes over the next two or three years. Such expectations seem built in to the share price, so I’m content to watch.

Medical devices

The solid characteristics of Smith & Nephew’s business led to a 50% upwards rebasing of the dividend last year and the forward yield is now running at around 2.5%. There’s also a share buy-back programme to cheer investors. Such moves make me optimistic about the firm’s total-return prospects from here, as demand seems unlikely to wane for the company’s products, such as joint replacements for knees hips and shoulders; tools for minimally invasive surgery; advanced wound dressings; and nuts, bolts, plates and nails for trauma surgery. The firm’s attractions seem embraced in the valuation, so I’m watching for now.

Publishing

In recent news, Pearson and Bertelsmann have completed the merger of Pearson’s Penguin with Random House to create Penguin Random House, a joint venture in which Pearson owns 47%. However, the education sector delivers around 90% of Pearson’s ongoing operating profit. The directors are expecting a difficult 2013 with various issues contributing to headwinds, such as pressures on education budgets and college enrolment numbers, and a shift in the firm’s business model from print sales to digital subscriptions. A restructuring-spend of £150m is targeted for the year, although that investment should generate some on-going cost savings. I’m watching the firm and expect to find out more in the end-of-July update.

Aerospace and defence

BAE Systems supplies many of the world’s fighter planes, radar, attack missiles, warships and munitions, but continuing pressure on government defence budgets in the company’s biggest markets, the UK and the US, means the directors are expecting muted growth in underlying earnings during 2013. Despite such challenges, the firm made good progress with cash flow and debt-reduction during 2012, and the constant nature of the business makes me optimistic about the dividend’s ability to contribute steadily towards total investor returns. There’s an attractive-looking 5.3% forward yield on offer at the current share-price level, but potential lack of forward earnings growth makes me cautious. I’m watching.

What now?

In my search for decent on-going total returns, I’m also considering a new Motley Fool report prepared by our top analysts that highlights five shares with seemingly impregnable, moat-like financial characteristics. “5 Shares To Retire On”, presents five shares that deserve consideration for any investor aiming to build wealth in the long run. For a limited period, the report is free. To download your copy now, click here.

> Kevin does not own any of the shares mentioned. The Motley Fool owns shares in Smith & Nephew.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

3 beaten-down shares to consider buying before the next bull market

Instead of waiting for stocks to start moving higher, Stephen Wright thinks investors should look for shares that might be…

Read more »

Black father and two young daughters dancing at home
Investing Articles

UK investors piled into these S&P 500 stocks during the Liberation Day sell-off…

Our writer wasn't surprised to see AJ Bell investors buying into the S&P 500 earlier this month, though one popular…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

A stunning 10% dividend-yield stock to consider for a Stocks and Shares ISA!

Harvey Jones says Stocks and Shares ISA investors should consider FTSE 250 fund manager aberdeen, a recovery stock that pays…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Here’s why the AstraZeneca share price dipped 3.7% in the FTSE 100 today

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a closer look.

Read more »

Photo of a man going through financial problems
Investing Articles

I asked ChatGPT to name 3 growth stocks to consider buying in today’s dip. Here they are!

Harvey Jones wants to use the stock market sell-off to buy some great value growth stocks and decided to call…

Read more »

Serious thinking young woman
Investing Articles

Are Associated British Food shares now one of the FTSE 100’s greatest bargains?

Associated British Food (ABF) shares have slumped on news of tough retail conditions. Is the FTSE 100 stock now too…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Growth Shares

Putting £450 in the stock market each month could be worth this much in a decade

Jon Smith explains which sectors could offer high growth potential for the coming decade and how to make the stock…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

As H1 results send the Associated British Foods (ABF) share price down 8%, is it time to buy?

This blip in the ABF share price on interim results day might be just the buying opportunity that patient long-term…

Read more »